Study design and rationale of "a multicenter, open-labeled, randomized controlled trial comparing three 2nd-generation drug-eluting stents in real-world practice" (CHOICE trial)

American Heart Journal

Volumn 166, Issue 2, 2013, Pages 224-229

  Youn, Young Jin ^a   Lee, Jun Won ^a   Ahn, Sung Gyun ^a   Lee, Seung Hwan ^a   Choi, Hyun Hee ^b   Choi, Hyunmin ^c   Choi, Cheol Ung ^d   Lee, Jin Bae ^e   Cho, Jang Hyun ^f   Kang, Tae Soo ^g   Cho, Byung Ryul ^h   Cha, Kwang Soo ⁱ   Kim, Moo Hyun ^j   Hyon, Min Su ^k   Cheong, Sang Sig ^l   Lim, Do Sun ^m   Han, Kyoo Rok ⁿ   Jeong, Myung Ho ^o   Park, Keum Soo ^p   Yoon, Junghan ^a  

^a Yonsei University Wonju   (South Korea)

^b Hallym University   (South Korea)

^c Inje University   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Catholic University of Daegu   (South Korea)

^f St Carollo Hospital   (South Korea)

^g Dankook University   (South Korea)

^h Kangwon National University   (South Korea)

ⁱ Pusan National University School of Medicine   (South Korea)

^j Dong A University College of Medicine   (South Korea)

^k Soonchunhyang University College of Medicine   (South Korea)

^l University of Ulsan   (South Korea)

^m College of Medicine   (South Korea)

ⁿ Kangdong Sacred Heart Hospital   (South Korea)

^o Chonnam National University Medical School   (South Korea)

^p Inha University Hospital   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLINX; POLYMER; UNCLASSIFIED DRUG;

ARTICLE; BIOLIMUS ELUTING STENT; COMPARATIVE EFFECTIVENESS; DEVICE SAFETY; DRUG ELUTING STENT; EVEROLIMUS ELUTING STENT; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; STUDY DESIGN; ZOTAROLIMUS ELUTING STENT;

ADULT; ALGORITHMS; CORONARY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PROSTHESIS DESIGN; SIROLIMUS;

EID: 84880921623     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.04.014     Document Type: Article

References (25)

1. A. Kastrati, A. Dibra, and J. Mehilli Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents Circulation 113 2006 2293 2300 (Pubitemid 43947975)
2. J.W. Moses, M.B. Leon, and J.J. Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323 (Pubitemid 37186209)
3. M. Pfisterer, H.P. Brunner-La Rocca, and P.T. Buser Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 48 2006 2584 2591 (Pubitemid 44881238)
4. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231 (Pubitemid 38067635)
5. D.R. Holmes Jr., D.J. Kereiakes, and W.K. Laskey Thrombosis and drug-eluting stents: an objective appraisal J Am Coll Cardiol 50 2007 109 118 (Pubitemid 47007739)
6. I. Iakovou, T. Schmidt, and E. Bonizzoni Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130 (Pubitemid 40617065)
7. D.E. Cutlip, D.S. Baim, and K.K. Ho Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials Circulation 103 2001 1967 1971 (Pubitemid 32322224)
8. P.A. Davlouros, E. Mavronasiou, and I. Xanthopoulou An optical coherence tomography study of two new generation stents with biodegradable polymer carrier, eluting paclitaxel vs. biolimus-A9 Int J Cardiol 2011
9. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678 (Pubitemid 46281313)
10. H. Roukoz, A.A. Bavry, and M.L. Sarkees Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up Am J Med 122 2009 581.e1 581.e10
11. A.J. Kirtane, A. Gupta, and S. Iyengar Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies Circulation 119 2009 3198 3206
12. L. Mauri, W.H. Hsieh, and J.M. Massaro Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 356 2007 1020 1029 (Pubitemid 46376802)
13. G.W. Stone, J.W. Moses, and S.G. Ellis Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008 (Pubitemid 46376800)
14. A. Caixeta, A.J. Lansky, and P.W. Serruys Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials JACC Cardiovasc Interv 3 2010 1220 1228
15. E. Kedhi, K.S. Joesoef, and E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
16. G.W. Stone, M. Midei, and W. Newman Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913 (Pubitemid 351574920)
17. G.W. Stone, A. Rizvi, and K. Sudhir Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial J Am Coll Cardiol 58 2011 19 25
18. P.W. Serruys, S. Silber, and S. Garg Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 136 146
19. S. Silber, S. Windecker, and P. Vranckx Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial Lancet 377 2011 1241 1247
20. G.G. Stefanini, B. Kalesan, and P.W. Serruys Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 378 2011 1940 1948
21. S. Windecker, P.W. Serruys, and S. Wandel Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
22. A. Hezi-Yamit, C. Sullivan, and J. Wong Novel high-throughput polymer biocompatibility screening designed for SAR (structure-activity relationship): application for evaluating polymer coatings for cardiovascular drug-eluting stents Comb Chem High Throughput Screen 12 2009 664 676
23. T.F. Luscher, J. Steffel, and F.R. Eberli Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications Circulation 115 2007 1051 1058 (Pubitemid 46328299)
24. P. Barlis, E. Regar, and P.W. Serruys An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study Eur Heart J 31 2010 165 176
25. E.H. Christiansen, L.O. Jensen, and P. Thayssen Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial Lancet 381 2013 661 669